L&C BIO Co.,LTD (KOSDAQ:290650)
53,300
+1,500 (2.90%)
Aug 20, 2026, 3:30 PM KST
L&C BIO Co.,LTD Revenue
L&C BIO Co.,LTD had revenue of 30.29B KRW in the quarter ending March 31, 2026, with 71.44% growth. This brings the company's revenue in the last twelve months to 98.10B, up 34.07% year-over-year. In the year 2025, L&C BIO Co.,LTD had annual revenue of 85.48B with 18.66% growth.
Revenue (ttm)
98.10B
Revenue Growth
+34.07%
P/S Ratio
14.65
Revenue / Employee
570.35M
Employees
172
Market Cap
1.44T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 85.48B | 13.44B | 18.66% |
| Dec 31, 2024 | 72.03B | 6.11B | 9.26% |
| Dec 31, 2023 | 65.93B | 13.35B | 25.40% |
| Dec 31, 2022 | 52.57B | 6.90B | 15.10% |
| Dec 31, 2021 | 45.68B | 12.70B | 38.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| SD Biosensor | 718.78B |
| CLASSYS | 369.10B |
| Vieworks | 243.11B |
| T&L Co., Ltd. | 157.91B |
| BioNote | 126.41B |
| Dongbang Medical | 117.37B |
| Shinhung | 104.15B |
| PCL, Inc. | 4.98B |